Australian small cap biotech Biotron ticks higher on Zika screen news


Sydney-based biotech Biotron has reported that two compounds in preclinical status have shown positive activity against the Zika virus, lifting shares in the firm.

The company said in a release to the Australian Stock Exchange that several unspecified compounds were screened at an "independent" facility in the United States. Shares rose to a 52-week high of A$0.074 this week from A$0.064 at the end of last week.

"One compound showed activity in the first round of screening and this result has been confirmed in repeat assays," the release said. "In a subsequent round of screening, a second compound has also shown to inhibit replication of Zika virus."


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Around a dozen firms around the world are working on potential Zika vaccines or therapies including Sanofi ($SNY) and Pennsylvania-based Inovio Pharma ($INO), with others at research stages like Biotron, and comes as the virus spreads in the Americas and with cases also now being reported in Asia.

The mosquito-borne virus has been linked as a cause of microcephaly during pregnancy.

- here's a release


Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.